Familial Adenomatous Polyposis (FAP)

Also known as: Familial Adenomatous Polyposis / Adenomatous Polyposis Coli / Polyposis coli / Familial polyposis

Drug	Drug Name	Drug Description
DB00482	Celecoxib	_Celecoxib_ is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and is also used to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name _Celebrex_. Celecoxib is available by prescription in capsule form [A34124]. By inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract. Celecoxib, however, poses less of an ulceration risk, owing to its decreased effect on gastric mucosal prostaglandin synthesis, when compared to placebo [A34152]. Interestingly, selective COX-2 inhibitors (especially _celecoxib_), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies [A34124].
DB00605	Sulindac	Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.

Drug	Drug Name	Target	Type
DB00482	Celecoxib	Prostaglandin G/H synthase 2	target
DB00482	Celecoxib	3-phosphoinositide-dependent protein kinase 1	target
DB00482	Celecoxib	Cytochrome P450 2C9	enzyme
DB00482	Celecoxib	Cytochrome P450 2D6	enzyme
DB00482	Celecoxib	Multidrug resistance-associated protein 4	transporter
DB00482	Celecoxib	Cytochrome P450 3A4	enzyme
DB00482	Celecoxib	Cytochrome P450 2C8	enzyme
DB00482	Celecoxib	Carbonic anhydrase 2	target
DB00482	Celecoxib	Carbonic anhydrase 3	target
DB00482	Celecoxib	ATP-binding cassette sub-family B member 5	target
DB00482	Celecoxib	ATP-binding cassette sub-family G member 2	target
DB00482	Celecoxib	Multidrug resistance protein 1	target
DB00482	Celecoxib	Bile salt export pump	transporter
DB00605	Sulindac	Prostaglandin G/H synthase 2	target
DB00605	Sulindac	Aldose reductase	target
DB00605	Sulindac	Prostaglandin G/H synthase 1	target
DB00605	Sulindac	Mitogen-activated protein kinase 3	target
DB00605	Sulindac	Peroxisome proliferator-activated receptor delta	target
DB00605	Sulindac	Prostaglandin D2 receptor 2	target
DB00605	Sulindac	Serum albumin	carrier
DB00605	Sulindac	Solute carrier family 22 member 6	transporter
DB00605	Sulindac	Cytochrome P450 1A1	enzyme
DB00605	Sulindac	Aldo-keto reductase family 1 member B10	target

Drug	Drug Name	Phase	Status	Count
DB00482	Celecoxib	2	Active Not Recruiting	1
DB00482	Celecoxib	2	Terminated	1
DB11672	Curcumin	2	Completed	1
DB11672	Curcumin	2	Withdrawn	1
DB06243	Eflornithine	2	Terminated	1
DB00530	Erlotinib	2	Recruiting	1
DB00331	Metformin	2	Recruiting	1
DB00482	Celecoxib	2 / 3	Completed	1
DB01586	Ursodeoxycholic acid	2 / 3	Completed	1
DB06243	Eflornithine	3	Active Not Recruiting	1
DB06243	Eflornithine	3	Withdrawn	1
DB00605	Sulindac	3	Active Not Recruiting	1
DB00482	Celecoxib	4	Terminated	1
DB11672	Curcumin	Not Available	Completed	1